This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
Journal of Cancer Research and Clinical Oncology Open Access 15 October 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Campbell PJ, Green AR . The myeloproliferative disorders. N Engl J Med 2006; 355: 2452–2466.
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–468.
Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A . Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008; 111: 2785–2789.
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.
Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG . Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274–4281.
Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41: 450–454.
Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41: 446–449.
Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41: 455–459.
Acknowledgements
The study was supported by funding from the Austrian Academy of Sciences, Austrian Science Fund (FWF, P20033-B11) and the MPD Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Olcaydu, D., Skoda, R., Looser, R. et al. The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23, 1924–1926 (2009). https://doi.org/10.1038/leu.2009.110
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.110
This article is cited by
-
JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
Journal of Cancer Research and Clinical Oncology (2023)
-
Mosaic loss of chromosome Y is associated with common variation near TCL1A
Nature Genetics (2016)
-
Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis
Annals of Hematology (2014)
-
The JAK2 46/1 haplotype (GGCC) in myeloproliferative neoplasms and splanchnic vein thrombosis: a pooled analysis of 26 observational studies
Annals of Hematology (2014)
-
Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations
Familial Cancer (2014)